European Directorate for the Quality of Medicines & HealthCare

What European Directorate for the Quality of Medicines & HealthCare does

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is an intergovernmental directorate of the Council of Europe, established in 1964 and headquartered in Strasbourg, France, that sets legally binding quality standards for medicines and healthcare products across Europe. Its flagship product is the European Pharmacopoeia (Ph. Eur.), currently in its 12th Edition and applicable in 39 European countries, which provides harmonised monographs, general chapters, and methods of analysis for active substances, excipients, and finished dosage forms. The directorate complements this with physical and chemical Ph. Eur. Reference Standards, the Certification of Suitability (CEP) procedure for verifying monograph compliance, the Official Medicines Control Laboratory (OMCL) Network coordinating 63 labs across 38 countries, the Biological Standardisation Programme, and technical guides covering blood, organ, and tissue/cell safety.

EDQM's technology stack is anchored in compendial content and operational databases rather than software platforms: it maintains the KNOWLEDGE Database (for CEP certification documentation), the Standard Terms Database (pharmaceutical dosage form and route of administration terminology), CombiStats (statistical analysis for biological assays), and Pharmeuropa (online publication of draft monographs for stakeholder consultation). The organisation holds ISO 17025 accreditation for its testing and calibration laboratory operations.

EDQM's revenue model is hybrid: it is primarily funded through Council of Europe member state contributions, supplemented by fee-based commercial streams including reference standards sales (via the EDQM Store), publication sales (pharmacopoeia editions and technical guides), CEP certification application and renewal fees, and proficiency testing scheme participation fees distributed across pharmaceutical manufacturers, national regulatory authorities, OMCLs, blood establishments, transplant centres, and consumer health producers. Its principal customer segments are the pharmaceutical industry (for quality control, CEP certification, and reference standards procurement) and regulatory authorities with OMCLs (for market surveillance, batch release, and proficiency testing), with secondary segments in blood establishments, transplant services, and the consumer health sector.

Name

European Directorate for the Quality of Medicines & HealthCare

Legal name

European Directorate for the Quality of Medicines & HealthCare

Website

https://edqm.eu

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

251–500 employees

Short description

EDQM is the Council of Europe's intergovernmental directorate that sets the legally binding European Pharmacopoeia, issues reference standards, and runs the CEP certification procedure and OMCL Network for pharmaceutical quality across 39 European countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Quality Standards

NAICS

Administration of Public Health Programs (92312), Medical Laboratories (621511)

SIC

Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAJADAI

Regulatory Affairs, Labeling & Advertising/Promotion Compliance

Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

SECONDARYHLAGAKAO

Third-Party/Outsourced Quality & Responsible Person Services (EU QP/RP, US Agent)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

SECONDARYBPAIAJAF

Public Health Laboratories & Diagnostic Oversight

Business & Public Services/Public Sector & Government Administration/Public Health Administration & Regulation

SECONDARYHLAJANAK

Health Systems Performance & Quality Measurement (Public Sector)

Healthcare & Life Sciences/Public Health, Government & Regulators/Health Program Evaluation & Surveillance

Keywords

• Medicines quality standards
• Healthcare quality oversight
• Pharmaceutical regulation
• Medicines policy
• Pharmacopoeia standards

Headquarters

HQ city

Strasbourg

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Reference Standards Sales: EDQM sells Ph. Eur. Reference Standards, WHO International Standards for Antibiotics (ISA), and WHO International Chemical Reference Substances (ICRS) to pharmaceutical manufacturers, testing laboratories, and regulatory authorities. Orders are processed through the EDQM store.
2. Publications Sales: Sale of EDQM publications including the European Pharmacopoeia (online and print editions), technical guides (Blood Guide, Organ Guide, Tissues and Cells Guide), and other regulatory guidance documents through the EDQM store.
3. CEP Certification Fees: Fees charged for Certificates of Suitability (CEP) applications, renewals, revisions, and related procedural services. Fees are published for Certificates of Suitability (CEP).
4. Proficiency Testing Scheme Fees: Fees for participation in proficiency testing scheme studies conducted by the OMCL Network, including physico-chemical, biological, and blood PTS programmes.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Core offering

European Directorate for the Quality of Medicines & HealthCare is identified by its name as a directorate focused on the quality of medicines and healthcare in Europe. No further details on its specific products, services, or operations are evidenced in the provided input data.

Product overview

EDQM offers a portfolio of interconnected products and services centered on medicines quality assurance and public health protection. The core offering is the European Pharmacopoeia (Ph. Eur.), a comprehensive set of legally enforced quality standards for pharmaceutical substances and dosage forms across 39 European countries. This is supported by Reference Standards (physical and chemical standards for quality testing) and the Certification of Suitability (CEP) programme that verifies compliance with Ph. Eur. monographs. The OMCL Network coordinates independent medicines testing across Europe, while the Biological Standardisation Programme develops standards for biological products. EDQM also publishes authoritative guidance documents (Blood Guide, Organ Guide, Tissues and Cells Guide) and maintains key databases including the KNOWLEDGE Database and Standard Terms Database. Software tools like CombiStats provide statistical analysis for biological assays, while publications like Pharmeuropa (for draft standards review), the European Paediatric Formulary, and European Drug Shortage Formulary address specific healthcare needs. The portfolio functions as an integrated regulatory ecosystem rather than standalone products.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• European Pharmacopoeia Issue 13.2 applicable in 39 European countries
• +2 more outcomes

Named customers4 records

Segments5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered core.

• SNOMED InternationalcoreStrategic or Co-development Partner · 1 September 2022EDQM and SNOMED International signed an agreement (effective September 2022) governing the creation, maintenance, and distribution of a terminology mapping between both organisations' terminologies. This collaboration supports interoperability between EDQM's standard terms and SNOMED CT for healthcare information systems.
• European CommissioncoreStrategic or Co-development PartnerEU Commission is listed as a partner, with EDQM standards leveraged in EU regulatory frameworks including the Falsified Medicines Directive and proposed new EU Regulation on Blood, Tissues and Cells. EDQM submitted input supporting the EU draft legislative proposal.
• European Medicines Agency (EMA)coreStrategic or Co-development PartnerEMA is listed as a partner with close collaboration on pharmaceutical regulatory matters, marketing authorisation procedures, and vaccine confidence advisory group activities.
• Heads of Medicines Agencies (HMA)coreStrategic or Co-development PartnerHMA is listed as a partner, representing the national medicines regulatory authorities of EU member states. Collaboration supports harmonised regulatory approaches across Europe.
• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO collaborates with EDQM on multiple fronts: WHO International Standards for Antibiotics (ISA) and WHO International Chemical Reference Substances (ICRS) are maintained and distributed by EDQM. WHO serves as observer in the Pharmacopoeial Discussion Group (PDG).
• Spanish Organización Nacional de Trasplantes (ONT)coreStrategic or Co-development PartnerONT provides invaluable support for the annual Newsletter Transplant publication, coordinating the collection and analysis of global organ donation and transplantation data that EDQM publishes each year.
• Pharmacopoeial Discussion Group (PDG)coreStrategic or Co-development PartnerPDG is a trilateral forum bringing together the European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia (JP), and United States Pharmacopeia (USP) for pharmacopoeial harmonisation, with WHO as observer. In October 2023, the Indian Pharmacopoeia Commission (IPC) joined as a fourth member, marking the first expansion in PDG's over 34-year history.
• Council of EuropecoreStrategic or Co-development PartnerEDQM is an integral part of the Council of Europe, operating as one of its key administrative entities. The Council of Europe provides the institutional framework, 46 member states, and broader mandate for EDQM's public health protection activities.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Chinese Pharmacopoeia Commission (ChP): ChP is China's national pharmacopoeia administered under the NMPA. It is a significant regional peer whose monographs, reference standards, and growing export market relevance parallel EDQM's role in Europe, though currently not a PDG member.
• Swissmedic (Swiss Agency for Therapeutic Products): Swissmedic is Switzerland's national medicines regulator with quality standards and laboratory oversight responsibilities. While smaller and national in scope, its Official Medicines Control Laboratory function and role in batch release testing make it functionally comparable to EDQM's OMCL Network coordination role at a country level.

Direct peers

• United States Pharmacopeia (USP): USP is the U.S. national pharmacopoeia setting quality standards for medicines and food ingredients. It is the most direct functional peer to EDQM's European Pharmacopoeia, serving the same monograph/reference standard/certification role in its respective jurisdiction and co-participating in the Pharmacopoeial Discussion Group (PDG).
• British Pharmacopoeia (BP): BP is the UK national pharmacopoeia published by the British Pharmacopoeia Commission. It maintains monographs and reference standards and historically aligned with Ph. Eur.; post-Brexit, it is a directly comparable national pharmacopoeia product competing for global reference-standard and publication revenue.
• Japanese Pharmacopoeia (JP): JP is Japan's official pharmacopoeia published by the Ministry of Health, Labour and Welfare. It is one of the three (now four, with IPC) PDG members and the most direct international counterpart to EDQM's Ph. Eur. in terms of monograph development, reference standards, and harmonisation work.

Broad incumbents

• World Health Organization (WHO): WHO sets global norms including the WHO International Standards for Antibiotics (ISA) and ICRS, which EDQM physically maintains and distributes. It is both a partner (observer in PDG) and a broad incumbent whose prequalification and pharmacopoeial reference programmes overlap with EDQM's standards-setting mandate.
• European Medicines Agency (EMA): EMA is the EU's central medicines regulator handling marketing authorisation, pharmacovigilance, and inspections. It is a close partner with EDQM (listed as a core alliance) and a broad incumbent whose regulatory scope overlaps with EDQM on pharmaceutical quality and biological product oversight across the EU.
• Food and Drug Administration (FDA) - CDER: The FDA's Center for Drug Evaluation and Research sets pharmaceutical quality expectations for the U.S. market and influences USP standards. It is a broad incumbent regulator whose quality frameworks intersect with EDQM's standards, reference testing, and batch release oversight globally.

Emerging players

• Indian Pharmacopoeia Commission (IPC): IPC publishes the Indian Pharmacopoeia and joined the PDG in October 2023 as its fourth member. It is an emerging pharmacopoeial authority whose growing generics and vaccine manufacturing base makes it a relevant regional peer to EDQM in standards harmonisation.

Others

• LGC Group (formerly LGC Standards / MHRA licensing): LGC is a UK-based life sciences measurement and standards company producing reference materials, including pharmaceutical reference standards under MHRA contracts. It operates as an adjacent infrastructure provider in the same standards ecosystem that EDQM serves, especially for non-Ph. Eur. monographed substances.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/edqm_news
• Facebookfacebook.com/EDQMCouncilofEurope
• LinkedInlinkedin.com/company/edqm

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about European Directorate for the Quality of Medicines & HealthCare